‘This is game changing for us,’ says US firm, Pharmgate, as it buys medicated feed additive producer

By Jane Byrne contact

- Last updated on GMT

We have essentially gone from being an active pharma ingredients (API) producer to a fully-fledged animal health company: Pharmgate
We have essentially gone from being an active pharma ingredients (API) producer to a fully-fledged animal health company: Pharmgate

Related tags: Animal health, Medicine, United states, North america

New Jersey based veterinary product supplier, Pharmgate, says its acquisition of Pennfield Animal Health, a producer of medicated in-feed and water soluble additives to tackle enteric diseases in livestock and poultry, is ‘transformative’.

‘The acquisitionrepresents a real game changer for us. We have essentially gone from being an active pharma ingredients (API) producer to a fully-fledged animal health company​,’ Colin Gray, CEO of Pharmgate, told feednavigator today.

The move sees it take over Pennfield's manufacturing and laboratory facilities as well as its sales and marketing operations in Nebraska.

Gray said the timing was right in respect of Pennfield’s growth, with the feed additive company long viewed as a potential takeover target by other market players: “It has some good pipeline projects, and we have acquired 19 active files in this deal.”

Pharmgate is a subsidiary of Jinhe Biotechnology of China, a manufacturer of chlortetracycline feed grade, chlortetracycline hydrochloride, salinomycin and other animal health compounds.

It was established in 2008 to enable its parent company access the feed and animal production industry in the US, Canada, Mexico, Latin America and Europe.

Joint venture in medicated feed

The CEO said the acquisition gives Pharmgate a strong base from which to continue its growth in the medicated feed additive and water soluble product sectors. Four years ago saw it enter a tie-up with UK antibiotics maker, Eco Animal Health, resulting in the establishment of the jointly owned Pharmgate Animal Health, with a focus on the North American market.

The acquisition of Pennfield also strengthens the New Jersey company's presence in Latin American markets, which Gray said offer opportunities but also plenty of challenges in terms of short-term gains: "These are big markets but also undisciplined ones, with an approach to regulatory oversight that differs somewhat from North America and Europe. There is a lot of competition from other medicated feed players, in addition to a lot of generics and price wars. But we didn't expect quick turnarounds - we are there for the long haul."

When asked about the impact of the US Food and Drug Administration (FDA)’s move to get drug companies to voluntarily remove growth enhancement and feed efficiency indications from the approved uses of their medically important antimicrobials such as chlortetracycline by 2017, the CEO said he expects little market disruption. 

“We forecast only a 3 to 5% reduction in overall volume of these products as a result of the FDA action,”​ said Gray.

Once manufacturers voluntarily make the changes requested by the agency, the affected antibiotics can then only be used in food-producing animals to treat, prevent or control disease under the order of or by prescription from a licensed veterinarian. 

Related news

Show more

Related products

Yeast nucleotides improve pig liver health

Yeast nucleotides improve pig liver health

Angel Yeast Co., Ltd. | 07-Jul-2022 | Research Study

Liver is one of the important organs in pigs. It has the functions of nutritional metabolism, detoxification, digestion and immunity, and 85% of pig diseases...

Related suppliers